Clareon Toric Study (T2-T9)

Clareon Toric Single Arm Study (T2-T9)

The purpose of this post-market study is to describe the long-term safety and performance of Clareon Toric Intraocular Lenses (IOLs).

Subjects will attend up to 12 scheduled visits (one preoperative visit, up to two surgical visits, and up to 9 postoperative visits) over the course of the study. The overall study duration is expected to be approximately 2 years. This study will be conducted in Canada.

Key Inclusion Criteria:

• Able to understand and sign the informed consent form.
• Willing and able to attend all scheduled study visits as required per protocol.
• Cataract in one or both eyes with planned extraction by conventional phacoemulsification.
• Astigmatism in the operative eye(s).
• Other protocol-defined inclusion criteria may apply.

Key Exclusion Criteria:

• Women of childbearing potential, currently pregnant, intend to become pregnant during the study, or nursing.
• History of retinal detachment, age-related macular degeneration, glaucoma, diabetic retinopathy, or any pathologic changes associated with the optic nerve.
• Clinically significant corneal disease that may, according to the Investigator's medical opinion, adversely affect visual outcomes.
• Clinically significant dry eye that would affect study measurements based on the Investigator's expert medical opinion.
• History of prior intraocular or corneal surgery.
• Other protocol-defined exclusion criteria may apply.